Novo Nordisk’s new CEO doubles down on obesity, diabetes push despite mixed Q3

Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion

Amgen confident in US biosimilar market’s strength as sales surge 52%

Sovato secures series B funding to advance remote robotic surgery platform

The company plans to use the funds to enhance its technology and forge new strategic partnerships with surgical robotics companies

UPS acquires Andlauer for $1.6 billion to strengthen global healthcare network

The integration of AHG’s specialized cold chain transportation and third-party logistics (3PL) solutions will significantly strengthen UPS Healthcare’s service offerings

EazeBio and UC Santa Cruz partner to advance instrument-free diagnostic platform

Collaboration aims to deliver rapid, lab-quality testing to communities worldwide – making precision health more accessible

Senores Pharma forms new subsidiary in US

Senores Pharmaceuticals (SPI) acquired 51% stake in Zoraya Pharmaceuticals

Novo Nordisk presents four new analyses on oral semaglutide 25 mg at ObesityWeek 2025

Oral semaglutide 25 mg was associated with the same weight loss efficacy in women with obesity regardless of menopausal stage, and patients reported improvements in physical function, respectively

Zydus wellness reports 31% growth in net sales in Q2 FY26

During the quarter, Zydus Wellness completed the acquisition of Comfort Click Limited and its subsidiaries

Cupid bags largest share in South Africa’s 5-year National Condom Program

Cupid has been allocated approximately 23.4 million units of female condoms per year

Marksans Pharma’s UK Arm Relonchem secures MHRA nod for Exemestane 25mg Tablets

Exemestane is a key therapeutic used in the treatment of certain types of breast cancer in postmenopausal women